SHEELA GADE: Open Payments
NPI 1114143757 · SAN MARINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$881 in 35 payments from 16 companies in 2025. Trend: 2023 $608 · 2024 $283 · 2025 $881
Food & beverage: $881
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $151 |
| ABBVIE INC. | 8 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $86 |
| Bausch Health US, LLC | 4 | $81 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Vanda Pharmaceuticals Inc. | 2 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 1 | $35 |
| Corium, LLC | 1 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
Products named: COBENFY, VRAYLAR, CAPLYTA, APLENZIN, Jornay PM, HETLIOZ, UZEDY, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
